Cardiac Troponin Elevation Beyond Type 1 Myocardial Infarction: A Systematic Review of Prognostic Significance and Cardiovascular Risk Stratification
Abstract
Cardiac troponin elevation is central to the diagnosis of myocardial injury, but its clinical interpretation remains challenging when type 1 myocardial infarction is absent. This systematic review evaluated the clinical and prognostic significance of elevated cardiac troponin in adults without type 1 myocardial infarction, with particular emphasis on type 2 myocardial infarction, critical illness-related myocardial injury, suspected acute coronary syndrome populations with minor myocardial injury, and acute or chronic heart failure-related myocardial injury. A systematic search of PubMed/MEDLINE, Scopus, and Web of Science identified six eligible clinical studies. The included evidence comprised prospective and retrospective cohort studies, secondary biomarker analyses of randomized trials, and trial-derived heart failure cohorts. Across heterogeneous clinical settings, troponin elevation was consistently associated with adverse outcomes, including all-cause mortality, cardiovascular mortality, heart failure hospitalization, cardiovascular death or heart failure rehospitalization, and greater clinical severity. In type 2 myocardial infarction and critical illness, troponin elevation identified high-risk patients despite the absence of classic plaque-rupture acute coronary syndrome. In heart failure populations, troponin appeared to function as a dynamic marker of myocardial stress, residual risk, and treatment-responsive injury. High-sensitivity assays further suggest that…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.